Novo lifts forecasts after strong demand for Wegovy weight-loss pill

Shares in Danish drugmaker surge on positive signal from results

Weight-loss drugs are changing dining as customers eat half their meals, take rest home, celebrity chef says

Celebrity chef Rocco DiSpirito reveals how Ozempic, delivery trends and rising costs are reshaping dining habits across the restaurant industry nationwide.

Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance

Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.

Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history.

Novo Nordisk on Wednesday narrowly improved its financial guidance for a year where it still sees profit and sales falling after the fastest take-up in weight-loss drug history for its Wegovy pill.

By Steve Goldstein

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

By Henry Saker-Clark

Supermicro stock soars on strong margin, revenue forecast

Skyworks Solutions forecasts higher revenue on strong chip demand

Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M

Novo Nordisk Soars After New Obesity Pill Momentum Lifts Guidance

Novo Nordisk Soars After New Obesity Pill Momentum Lifts Guidance Novo Nordisk shares jumped as much as 9% in Copenhagen, suggesting the stock may finally be bottoming out after a vicious multi-year bear market. The move followed the Danish drugmaker's decision to raise its 2026 guidance ranges for adjusted sales and adjusted operating profit, citing solid momentum in Wegovy sales. Novo now expects full-year sales and profit declines of around 12%, down from a previous forecast ...

By Tyler Durden